Inari gains as FlowTriever cuts mortality risk by 90% in pulmonary embolism

Mar. 06, 2023 9:11 AM ETInari Medical, Inc. (NARI)By: Dulan Lokuwithana, SA News Editor

Inari Medical (NASDAQ:NARI) added ~5% pre-market Monday after a study indicated that the company’s FDA-cleared FlowTriever device cut the mortality risk by 90% in patients with high-risk pulmonary embolism.
The FLAME study was a prospective study designed to evaluate interventional treatment in high-risk PE patients who typically have a mortality rate of 25-50%.
According to Inari (NARI), the trial met the primary endpoint for the FlowTriever arm, which indicated a mortality rate of 1.9%, representing a 90% decline compared to the 29.5% mortality rate seen in those who received other therapies.
The investigators ended the study early “due to overwhelmingly positive outcomes in the FlowTriever patients,” the company added.
“The results of the trial will have an immediate impact on the treatment of high-risk PE patients and will ultimately change clinical practice guidelines for that population,” Inari’s (NARI) medical chief Thomas Tu remarked.
Seeking Alpha contributor, Zach Bristow reaffirmed his Buy rating on the stock ahead of the readout.